2-methyl-3-hydroxy-6-fluoroaniline | 364328-07-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-methyl-3-hydroxy-6-fluoroaniline
• 英文别名: 3-amino-4-fluoro-2-methyl-phenol；3-amino-4-fluoro-2-methylphenol
• CAS: 364328-07-4
• 化学式: C₇H₈FNO
• 分子量: 141.145
• InChiKey: OIAWIBFDSKVGHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-3-hydroxy-6-fluoroaniline 在 硼烷四氢呋喃络合物 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 4-fluoro-3-[[2-fluoro-5-(3-fluorophenyl)-3-methylphenyl]methylamino]-2-methylphenol
  参考文献：
  名称：

  [EN] ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  [FR] DÉRIVÉS D'ANILINE, LEUR PRÉPARATION ET LEUR APPLICATION THÉRAPEUTIQUE

  摘要：

  公开号：

  WO2013037705A9
• 作为产物：
  描述：

  tert-butyl N-tert-butoxycarbonyl-N-(6-fluoro-3-hydroxy-2-methyl-phenyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以97%的产率得到2-methyl-3-hydroxy-6-fluoroaniline
  参考文献：
  名称：

  [EN] ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  [FR] DÉRIVÉS D'ANILINE, LEUR PRÉPARATION ET LEUR APPLICATION THÉRAPEUTIQUE

  摘要：

  公开号：

  WO2013037705A9

文献信息

• [EN] QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS QUINAZOLÉINE
  申请人：CANCER REC TECH LTD

  公开号：WO2015079251A1

  公开（公告）日：2015-06-04

  The present invention relates to quinazoline compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, R3, R4, R5, R6 and R7 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

  本发明涉及式I的喹唑啉化合物，其作为RET（重排基因转座）激酶酶活性的抑制剂：（式（I）），其中X，R1，R2，R3，R4，R5，R6和R7如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及RET激酶活性的疾病或症状中的用途。
• The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
  作者：Rebecca Newton、Katherine A. Bowler、Emily M. Burns、Philip J. Chapman、Emma E. Fairweather、Samantha J.R. Fritzl、Kristin M. Goldberg、Niall M. Hamilton、Sarah V. Holt、Gemma V. Hopkins、Stuart D. Jones、Allan M. Jordan、Amanda J. Lyons、H. Nikki March、Neil Q. McDonald、Laura A. Maguire、Daniel P. Mould、Andrew G. Purkiss、Helen F. Small、Alexandra I.J. Stowell、Graeme J. Thomson、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1016/j.ejmech.2016.01.039

  日期：2016.4

  therefore, a clinical need for more specific RET kinase inhibitors. Herein we report our efforts towards identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-based drug design. Phenolic anilinoquinazolines exemplified by 6 showed improved affinities towards RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic

  受体酪氨酸激酶 RET 的失调与甲状腺髓样癌、一小部分肺腺癌、耐内分泌乳腺癌和胰腺癌有关。有几种临床批准的多激酶抑制剂将 RET 作为二级药理学，但其他活性，最显着的 KDR 抑制，会导致剂量限制性毒性。因此，临床需要更特异性的 RET 激酶抑制剂。在这里，我们报告了我们使用凡德他尼1作为基于结构的药物设计的起点来鉴定有效和选择性 RET 抑制剂的努力。酚类苯胺基喹唑啉以6为例显示对 RET 的亲和力有所提高，但不出所料，代谢清除率高。减轻苯酚代谢倾向的努力导致发现侧翼取代基不仅提高了肝细胞稳定性，而且还可以显着提高选择性。最终确定了36 个；一种有效的 RET 抑制剂，对 KDR 的选择性大大提高。
• ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：Feutrill John

  公开号：US20140350019A1

  公开（公告）日：2014-11-27

  The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C 1 -C 6 )alkyl or a CN; R1b represents H, an halogen or a (C 1 -C 6 )alkyl; R1c represents H or a (C 1 -C 6 )alkyl; R2 represents H, an halogen, an OH, an O—(C 1 -C 6 )alkyl or (C 1 -C 6 )alkyl; R3 represents H, an halogen, a (C 1 -C 6 )alkyl, an OH, an O—(C 1 -C 6 )alkyl, a CONH 2 or CN; R4 represents H, an halogen or a (C 1 -C 6 )alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C 1 -C 6 )alkyl, or one of its enantiomers.

  本发明涉及公式（I）的苯胺衍生物，其制备方法和治疗应用，例如用于治疗青光眼：公式（I），其中R1a代表H、卤素、（C1-C6）烷基或CN；R1b代表H、卤素或（C1-C6）烷基；R1c代表H或（C1-C6）烷基；R2代表H、卤素、OH、O-（C1-C6）烷基或（C1-C6）烷基；R3代表H、卤素、（C1-C6）烷基、OH、O-（C1-C6）烷基、CONH2或CN；R4代表H、卤素或（C1-C6）烷基；R5代表H或F；R7代表H或F；R8代表H或F；R9代表H或（C1-C6）烷基，或其对映体。
• Aniline derivatives, their preparation and their therapeutic application
  申请人：Feutrill John

  公开号：US09249085B2

  公开（公告）日：2016-02-02

  The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.

  本发明涉及公式（I）的苯胺衍生物，其制备及其治疗应用，例如治疗青光眼：公式（I），其中R1a代表H、卤素、（C1-C6）烷基或CN; R1b代表H、卤素或（C1-C6）烷基; R1c代表H或（C1-C6）烷基; R2代表H、卤素、羟基、O-（C1-C6）烷基或（C1-C6）烷基; R3代表H、卤素、（C1-C6）烷基、羟基、O-（C1-C6）烷基、CONH2或CN; R4代表H、卤素或（C1-C6）烷基; R5代表H或F；R7代表H或F；R8代表H或F；R9代表H或（C1-C6）烷基，或其对映体之一。
• Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
  作者：Allan M. Jordan、Habiba Begum、Emma Fairweather、Samantha Fritzl、Kristin Goldberg、Gemma V. Hopkins、Niall M. Hamilton、Amanda J. Lyons、H. Nikki March、Rebecca Newton、Helen F. Small、Swamy Vishwanath、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1016/j.bmcl.2016.03.100

  日期：2016.6

  We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging. (C) 2016 Elsevier Ltd. All rights reserved.